Immunovant IMVT announced top-line data from a late-stage study of its investigational candidate, batoclimab, for myasthenia ...

Immunovant (NASDAQ:IMVT – Free Report) had its price objective decreased by Bank of America from $38.00 to $33.00 in a ...

Immunovant's (NASDAQ:IMVT) stock and Roivant Sciences (ROIV) stock fall after trial data for the former's autoimmune disease ...

Leerink Partners analyst Thomas Smith reiterated a Buy rating on Immunovant (IMVT – Research Report) yesterday and set a price target of ...

Immunovant, Inc. had positive results for batoclimab in trials for Myasthenia Gravis & CIDP; Thyroid Eye Disease data ...

Switching to IMVT-1402 extends the head starts Immunovant has already ceded to its rivals. Argenx won FDA approval for ...

Stifel analyst Alex Thompson raised the firm’s price target on Immunovant (IMVT) to $61 from $58 and keeps a Buy rating on the shares following ...

Immunovant (NASDAQ:IMVT – Get Free Report)‘s stock had its “buy” rating restated by equities researchers at HC Wainwright in ...

Immunovant, Inc. (NASDAQ:IMVT) released topline results from its Phase 3 study of batoclimab in myasthenia gravis (MG) and ...

Immunovant will use results from its Phase III myasthenia gravis study to support pipeline candidate IMVT-1402 over the trial ...